Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

ubstitute for form 1449A/PTO

NOV 0 6 2002

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of 2

	- 17	_~)	
Application Number	10/067,996	$\overline{\mathbb{H}}$	00
Filing Date	February 8, 2002		2
First Named Inventor	Allen T. Hopper	Ш	
Group Art Unit	Unassgined	()	/ (
Examiner Name	Unassigned		0
Attorney Docket Number	MEMORY-2	~ H	\overline{z}

U.S. PATENT DOCUMENTS							
Examiner Initials *	Cite No.1	U.S. Patent Doo Number Kind (if kn	Code ²	T	Patentee or Applicant Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KI	1	5,013,829			NAIR et al.	05-07-1991	
			J				;
				<u> </u>			:
	-		1	 			<u> </u>
	 	 	+	 .			
			+	 		•	
				1			:
			ļ	<u> </u>			
				 			
	<u> </u>		+	 	· · · · · · · · · · · · · · · · · · ·		<u> </u>
	 	 	+				
			 	†			
				-			
			↓				•
		<u> </u>	_	ļ <u>. </u>			·
			1	1			

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	For Office ³	eign Patent Do	Kind Code	e ⁵	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
			T	(′ 			riguies Appeai	
··-			 		+				
		 					· · · · · · · · · · · · · · · · · · ·		<u> </u>
-		+							 -
			<u> </u>						!
		+	 				· · · · · · · · · · · · · · · · · · ·		
		 	 					·	
					-				
					\dashv			,	· · · · ·
		+	 						l
	<u> </u>	- 	<u> </u>		\dashv				
 		+	-						<u> </u>
		<u> </u>							<u> </u>
		- 			o				l

Examiner Signature	At Chy No	apt	Date Considered	June 12	2003

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

Applicant is to place a check mark hee if English language Translation is



ase type a plus sign (+) inside this box -> | +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known **Application Number** 10/067,996 INFORMATION DISCLOSURE February 8, 2002 Filing Date STATEMENT BY APPLICANT First Named Inventor Allen T. Hopper **Group Art Unit** Unassgined (use as many sheets as necessary) **Examiner Name** Unassigned MEMORY-2 Sheet of Attorney Docket Number

Examiner Initials * Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		Τ²	
KU	2	THOMAS C. MCKENZIE et al., "The Gomberg-Bachmann Reaction of Purines", <u>J. Heterocyclic Chem.</u> , May-Jun 1987, pp. 859-861, Vol. 24	
	3	VASU NAIR et al., "Novel, Stable Congeners of Antiretroviral Compound 2', 3'- Dideoxyadenosine," <u>J. Am. Chem. Soc.</u> , 1989, pp. 8502-8504, Vol. 111	
	4	JAMES E. KELLEY et al., "Antirhinovirus structure-activity relationships of 6-substituted-9-(4-methylbenzyl)-2-trifluoromethyl-9H-purines," <u>Eur. J. Med. Chem.</u> , 1990, pp. 131-135, Vol. 25	
	5	JEAN-JACQUES BOURGUIGNON et al., *9-Benzyladenines: Potent and Selective cAMP Phosphodiesterase Inhibitors,* J. Med. Chem, 1997, pp. 1768-1770, Vol. 40	
	6	JAMES L. KELLEY et al., "6-(Alkylamino)-9-alkylpurines. A New Class of Potential Antipsychotic Agents," J. Med. Chem., 1997, pp. 3207-3216, Vol. 40	
	7	ELISABETH BOICHOT et al., "Anti-Inflammatory Activities of a New Series of Selective Phosphodiesterase 4 Inhibitors Derived from 9- Benzyladenine," The Journal Of Pharmacology And Experimental Therapeutics, 2000, pp. 647-653, Vol 292, No.2	
	8	V. VAIR, "Hydrolysis of Dideoxgenated Purine Nucleosides: Effect of Modification of the Base Moiety", <u>J. ORG.</u> <u>CHEM</u> , 1990, pp. 3695-3697, vol. 55, no. 11	
	9	H. NAGANO et al., "Fluorine-Containing Potential Anticancer agents. II. Syntheses Trifuoromethylpurines and Trifluormethylthiazolopyrimidines", <u>J. MED. CHEM.</u> , 1964, pp. 215-220, vol. 7, no. 2	
	10	VASU NAIR et al., "Inhibition of mammalian adenosine deaminase by novel functionalized 2', 3'-dideoxyadenosines", <u>BIOCHIM. BIOPHYS. ACTA.</u> 1991, pp. 121-123, vol. 1078, no. 1	
	11	PATENT ABSTRACTS OF JAPAN, vol. 2000, no. 6, September 22, 2000, JP 200 072773, March 7, 2000	
d_	12	PATENT ABSTRACTS OF JAPAN, vol. 1999, no. 12, October 29, 1999, JP 11 180982, July 6, 1999	
		· ·	

	Examiner Signature	A Why Ma	Date Considered	JUNE 12, 203
--	-----------------------	----------	--------------------	--------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

NOV 0 7 2002 TECH CENTER 1600/2900

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.